Evoke Pharma Inc (EVOK) 7.41 $EVOK
Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 16, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Evoke Pharma Reports Fourth Quarter and Year End 2013 Results
GlobeNewswire - Tue Mar 25, 3:30PM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter and year ended December 31, 2013.
Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter 2013 Financial Results
GlobeNewswire - Mon Mar 10, 9:02AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the Fourth Quarter of 2013 on Tuesday, March 25, 2014, after the close of the market.
Evoke Pharma to Present at 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 7:30AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer, R.Ph., will be presenting at the 26 Annual ROTH Conference, being held March 10-12, 2014 at the Ritz-Carlton in Dana Point, California.
Diabetic Gastroparesis - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/7ctztm/diabetic) has announced the addition of the "Diabetic Gastroparesis - Pipeline Review, H1 2014" report to their offering. 'Diabetic Gastroparesis - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Gastroparesis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis. Scope - A snapshot of the global therapeutic scenario for Diabetic Gastroparesis. - A review of the Diabetic Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diabetic Gastroparesis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Diabetic Gastroparesis Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles metoclopramide hydrochloride - Drug Profile RM-131 - Drug Profile velusetrag - Drug Profile Non-Antibiotic Macrolide Program for Gastric Disorders - Drug Profile TC-6499 - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Theravance, Inc. Evoke Pharma, Inc. Targacept, Inc. Cempra, Inc. Rhythm Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/7ctztm/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Evoke Pharma Study Reports Positive Results of Metoclopramide Nasal Spray for Gastroparesis in Diabetics
GlobeNewswire - Wed Jan 22, 7:30AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the publication of a study that found intranasal delivery of metoclopramide to be more effective in managing symptoms of diabetic gastroparesis compared to the marketed oral tablet formulation of metoclopramide.
Diabetic Gastroparesis Global Clinical Trials Review, H2 2013 Report Available Now
M2 - Mon Jan 13, 10:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/kd5vzq/diabetic) has announced the addition of the "Diabetic Gastroparesis Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Diabetic Gastroparesis Global Clinical Trials Review, H2, 2013" provides data on the Diabetic Gastroparesis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Gastroparesis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diabetic Gastroparesis. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: - Axcan Pharma, Inc. - Duke University - Evoke Pharma, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Goteborg University - Malmo University Hospital - Novartis AG - Osaka City University - Questcor Pharmaceuticals, Inc. - Rabin Medical Center - Rhythm Pharmaceuticals - Shaare Zedek Medical Center - Targacept, Inc. - Theravance, Inc. - Tranzyme Pharma, Inc. - Vienna General Hospital - Yokohama City University For more information visit http://www.researchandmarkets.com/research/kd5vzq/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Evoke Pharma to Present at Biotech Showcase(TM) 2014
GlobeNewswire - Tue Jan 07, 7:31AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer is scheduled to present at Biotech Showcase(TM) 2014, being held January 13-15, 2014 in San Francisco, Calif.
Evoke Pharma Strengthens Executive Team With Appointments of Chief Medical Officer and Senior Director of Clinical Operations
GlobeNewswire - Mon Dec 02, 7:30AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, announced today the appointment of Marilyn R. Carlson, D.M.D., M.D., RAC, as Chief Medical Officer and Wayne Alves, Ph.D., as Senior Director of Clinical Operations. These two executives will focus on the initiation and execution of the company's Phase 3 clinical trial of EVK-001 for gastroparesis, which is expected to commence in the first half of 2014.
Evoke Pharma Selects SynteractHCR as Contract Research Organization for Phase 3 Trial of EVK-001 for Gastroparesis
GlobeNewswire - Tue Nov 26, 7:30AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the selection of SynteractHCR, Inc. to serve as its primary contract research organization ("CRO"
for its upcoming Phase 3 clinical trial of EVK-001. EVK-001 is a novel metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. Selection of SynteractHCR follows the successful completion of Evoke's 287 patient, multi-center Phase 2b clinical trial of EVK-001, for which SynteractHCR was the primary CRO.
Strategic Acquisitions, New Drug Applications, Licensing Agreements, and Financial Results - Research Report on Horizon Pharma, NPS Pharmaceuticals, Spherix, Evoke Pharma, and POZEN
PR Newswire - Fri Nov 22, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Horizon Pharma, Inc. (NASDAQ: HZNP), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Spherix Inc. (NASDAQ: SPEX), Evoke Pharma, Inc. (NASDAQ: EVOK), and POZEN Inc. (NASDAQ: POZN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 16, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Evoke Pharma Reports Fourth Quarter and Year End 2013 Results
GlobeNewswire - Tue Mar 25, 3:30PM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter and year ended December 31, 2013.
Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter 2013 Financial Results
GlobeNewswire - Mon Mar 10, 9:02AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the Fourth Quarter of 2013 on Tuesday, March 25, 2014, after the close of the market.
Evoke Pharma to Present at 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 7:30AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer, R.Ph., will be presenting at the 26 Annual ROTH Conference, being held March 10-12, 2014 at the Ritz-Carlton in Dana Point, California.
Diabetic Gastroparesis - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/7ctztm/diabetic) has announced the addition of the "Diabetic Gastroparesis - Pipeline Review, H1 2014" report to their offering. 'Diabetic Gastroparesis - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Gastroparesis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis. Scope - A snapshot of the global therapeutic scenario for Diabetic Gastroparesis. - A review of the Diabetic Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diabetic Gastroparesis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Diabetic Gastroparesis Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles metoclopramide hydrochloride - Drug Profile RM-131 - Drug Profile velusetrag - Drug Profile Non-Antibiotic Macrolide Program for Gastric Disorders - Drug Profile TC-6499 - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Theravance, Inc. Evoke Pharma, Inc. Targacept, Inc. Cempra, Inc. Rhythm Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/7ctztm/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Evoke Pharma Study Reports Positive Results of Metoclopramide Nasal Spray for Gastroparesis in Diabetics
GlobeNewswire - Wed Jan 22, 7:30AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the publication of a study that found intranasal delivery of metoclopramide to be more effective in managing symptoms of diabetic gastroparesis compared to the marketed oral tablet formulation of metoclopramide.
Diabetic Gastroparesis Global Clinical Trials Review, H2 2013 Report Available Now
M2 - Mon Jan 13, 10:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/kd5vzq/diabetic) has announced the addition of the "Diabetic Gastroparesis Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Diabetic Gastroparesis Global Clinical Trials Review, H2, 2013" provides data on the Diabetic Gastroparesis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Gastroparesis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diabetic Gastroparesis. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: - Axcan Pharma, Inc. - Duke University - Evoke Pharma, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Goteborg University - Malmo University Hospital - Novartis AG - Osaka City University - Questcor Pharmaceuticals, Inc. - Rabin Medical Center - Rhythm Pharmaceuticals - Shaare Zedek Medical Center - Targacept, Inc. - Theravance, Inc. - Tranzyme Pharma, Inc. - Vienna General Hospital - Yokohama City University For more information visit http://www.researchandmarkets.com/research/kd5vzq/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Evoke Pharma to Present at Biotech Showcase(TM) 2014
GlobeNewswire - Tue Jan 07, 7:31AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer is scheduled to present at Biotech Showcase(TM) 2014, being held January 13-15, 2014 in San Francisco, Calif.
Evoke Pharma Strengthens Executive Team With Appointments of Chief Medical Officer and Senior Director of Clinical Operations
GlobeNewswire - Mon Dec 02, 7:30AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, announced today the appointment of Marilyn R. Carlson, D.M.D., M.D., RAC, as Chief Medical Officer and Wayne Alves, Ph.D., as Senior Director of Clinical Operations. These two executives will focus on the initiation and execution of the company's Phase 3 clinical trial of EVK-001 for gastroparesis, which is expected to commence in the first half of 2014.
Evoke Pharma Selects SynteractHCR as Contract Research Organization for Phase 3 Trial of EVK-001 for Gastroparesis
GlobeNewswire - Tue Nov 26, 7:30AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the selection of SynteractHCR, Inc. to serve as its primary contract research organization ("CRO"
for its upcoming Phase 3 clinical trial of EVK-001. EVK-001 is a novel metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. Selection of SynteractHCR follows the successful completion of Evoke's 287 patient, multi-center Phase 2b clinical trial of EVK-001, for which SynteractHCR was the primary CRO. Strategic Acquisitions, New Drug Applications, Licensing Agreements, and Financial Results - Research Report on Horizon Pharma, NPS Pharmaceuticals, Spherix, Evoke Pharma, and POZEN
PR Newswire - Fri Nov 22, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Horizon Pharma, Inc. (NASDAQ: HZNP), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Spherix Inc. (NASDAQ: SPEX), Evoke Pharma, Inc. (NASDAQ: EVOK), and POZEN Inc. (NASDAQ: POZN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
